Sign In
Buy ASH
$57.58
-0.430 (-0.741%)
At Close: Jun 02, 2026
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
09:04am, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
09:01am, Monday, 03'rd Nov 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit
- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody - Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / No
Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosu
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
09:00am, Monday, 03'rd Nov 2025
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
09:00am, Monday, 03'rd Nov 2025
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that resu
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for p
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
09:00am, Monday, 03'rd Nov 2025
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest p
Head-To-Head Contrast: DoorDash (NASDAQ:DASH) vs. Zillow Group (NASDAQ:Z)
01:56am, Friday, 31'st Oct 2025
DoorDash (NASDAQ: DASH - Get Free Report) and Zillow Group (NASDAQ: Z - Get Free Report) are both large-cap computer and technology companies, but which is the superior investment? We will contrast th
Ashland changes start time for fourth-quarter fiscal 2025 earnings conference call webcast
05:01pm, Thursday, 30'th Oct 2025
WILMINGTON, Del., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) has changed the start time of its fourth-quarter fiscal 2025 earnings webcast being held on Wednesday, November 5, 2025. Th
Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for
11:07am, Tuesday, 28'th Oct 2025
Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ashland sets date for fourth-quarter fiscal 2025 earnings release and conference call webcast
07:00am, Thursday, 23'rd Oct 2025
WILMINGTON, Del., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2025 earnings release at approximately 5 p.m.
Yousif Capital Management LLC Reduces Stock Position in Ashland Inc. $ASH
05:58am, Thursday, 23'rd Oct 2025
Yousif Capital Management LLC cut its holdings in shares of Ashland Inc. (NYSE: ASH) by 3.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Comm
